Navigation Links
Kensey Nash Announces a Manufacturing Agreement with and Minority Investment in Orteq Sports Medicine
Date:1/3/2011

EXTON, Penn., Jan. 3, 2011 /PRNewswire/ -- Kensey Nash Corporation (Nasdaq: KNSY), a regenerative medicine company, announced it has entered into a manufacturing agreement with, and made a minority equity investment in, Orteq Sports Medicine, a medical device company specializing in the field of biodegradable polymer technology for meniscus repair.

Orteq, with headquarters in London, UK, created Actifit®, a biocompatible synthetic meniscal scaffold offering sports medicine surgeons a new arthroscopic option for the treatment of irreparable partial meniscal tears.  Orteq expects to receive FDA approval to start its Actifit® clinical trial in the U.S. in 2011.  Actifit® received its CE Mark approval in 2008 and is currently available throughout Europe.

The FDA approval of the U.S. clinical trial will trigger an additional $1 million investment in Orteq, which will, on a cumulative basis, total approximately $5 million which includes the exclusive worldwide manufacturing rights and represents an approximate 10% ownership in Orteq.

Under the terms of the manufacturing agreement, Kensey Nash will receive a transfer price and royalties.  Other terms of the agreement were not disclosed.

"Kensey Nash is very pleased to work with the talented and innovative Orteq team and its world-renowned clinicians who have generated outstanding clinical evidence," commented Joseph W. Kaufmann, President and CEO of Kensey Nash.  "We believe Orteq's Actifit meniscus repair product can provide a safe and effective repair that will address over a $1 billion target market potential in sports medicine.  We look forward to a successful and long term relationship," he concluded.

"We are delighted that Kensey Nash Corporation has made an investment in Orteq.  The Kensey Nash team brings us world-class expertise to manufacturing and developing safe, effective and innovative medical devices for our customers, sports medicine surgeons," commented Dianne Blanco, CEO of Orteq.

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology.  The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials.  The Company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including, the cardiology, orthopaedic, sports medicine, spine, endovascular and general surgery markets.  For more information, visit www.kenseynash.com.

About Orteq Sports Medicine.  Orteq, with headquarters in London, UK and manufacturing, R&D in Groningen, the Netherlands, was established in 2005 to develop and commercialize solutions for orthopaedic/sports injuries.  Orteq has developed a biodegradable, biocompatible polymer scaffold, Actifit®, specifically designed to support tissue ingrowth and regeneration in the meniscus, a fibrocartilage cushion in the knee.  For more information, visit www.orteq.com.

Kensey Nash Cautionary Note for Forward-Looking Statements.  This press release contains forward-looking statements that reflect the current expectations of Kensey Nash Corporation (the "Company") about its prospects and opportunities.  The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "would," "should," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements.  The Company cautions that a number of risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, Orteq's success in selling its meniscus repair product pursuant to the agreement(or otherwise), the Company's success in its manufacturing efforts of Actifit®, the success of U.S. trials with respect to the Orteq's meniscus repair products and completion of additional clinical trials in both the U.S. and Europe to support regulatory approval of future generations of its products, competition from other technologies, Orteq's success in distributing its products into the marketplace, as well as tax and other risks associated with healthcare reform, economic conditions and foreign currency fluctuations.  For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosures under "Risk Factors" in those filings.  Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kensey Nash Announces IDE Submission for Cartilage Repair Device
2. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
3. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
4. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
5. Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
6. Kensey Nash Announces $30 Million Share Buyback
7. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
8. Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum
9. Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
10. Kensey Nash to Present at the Ninth Annual JMP Securities Research Conference
11. KENSEY NASH Receives FDA 510(k) Clearance for ECM Product, Meso BioMatrix Surgical Mesh
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider of ... other difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene ... System is a complete system for culturing and transfecting human pluripotent stem ...
(Date:6/24/2016)... ... June 24, 2016 , ... Southern ... DDS, are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s Mission of ... the Gateway Convention Center in Collinsville. , They expect to treat ...
Breaking Medicine News(10 mins):